EA202090428A1 - HETEROCYCLIC COMPOUND AND ITS APPLICATION - Google Patents

HETEROCYCLIC COMPOUND AND ITS APPLICATION

Info

Publication number
EA202090428A1
EA202090428A1 EA202090428A EA202090428A EA202090428A1 EA 202090428 A1 EA202090428 A1 EA 202090428A1 EA 202090428 A EA202090428 A EA 202090428A EA 202090428 A EA202090428 A EA 202090428A EA 202090428 A1 EA202090428 A1 EA 202090428A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heterocyclic compound
application
narcolepsy
prevention
salt
Prior art date
Application number
EA202090428A
Other languages
Russian (ru)
Other versions
EA039459B1 (en
Inventor
Юити Кадзита
Сатоси Миками
Юхэи Миянохана
Тацуки Койке
Масаки Даини
Норио Оябу
Масаки Огино
Кохеи Такеути
Еситеру Ито
Норихито Токунага
Такахиро Сугимото
Тохру Миядзаки
Цунео Ода
Ясутака Хоаси
Ясуси Хаттори
Кейсуке Имамура
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Priority claimed from PCT/JP2018/029696 external-priority patent/WO2019027058A1/en
Publication of EA202090428A1 publication Critical patent/EA202090428A1/en
Publication of EA039459B1 publication Critical patent/EA039459B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к гетероциклическому соединению, обладающему активностью агониста рецептора орексина 2 типа. Соединение, представленное формулой (I), где каждый символ принимает значение, определенное в описании, или его соль может применяться в качестве средства для профилактики или лечения нарколепсии.The invention relates to a heterocyclic compound having orexin type 2 receptor agonist activity. The compound represented by the formula (I), wherein each symbol takes on the meaning defined in the specification, or a salt thereof, can be used as an agent for the prevention or treatment of narcolepsy.

EA202090428A 2017-12-25 2018-08-02 Heterocyclic compound and use thereof as an agent for the treatment of diseases associated with an orexin type 2 receptor EA039459B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017248495 2017-12-25
PCT/JP2018/029696 WO2019027058A1 (en) 2017-08-03 2018-08-02 Heterocyclic compound and use thereof

Publications (2)

Publication Number Publication Date
EA202090428A1 true EA202090428A1 (en) 2020-05-21
EA039459B1 EA039459B1 (en) 2022-01-28

Family

ID=70847671

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202192934A EA202192934A1 (en) 2017-12-25 2018-08-02 HETEROCYCLIC COMPOUND AND ITS APPLICATIONS
EA202090428A EA039459B1 (en) 2017-12-25 2018-08-02 Heterocyclic compound and use thereof as an agent for the treatment of diseases associated with an orexin type 2 receptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202192934A EA202192934A1 (en) 2017-12-25 2018-08-02 HETEROCYCLIC COMPOUND AND ITS APPLICATIONS

Country Status (1)

Country Link
EA (2) EA202192934A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527807B2 (en) * 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
DK3411358T3 (en) * 2016-02-04 2022-01-17 Takeda Pharmaceuticals Co Substituted piperidine compound and its use.

Also Published As

Publication number Publication date
EA202192934A1 (en) 2022-02-09
EA039459B1 (en) 2022-01-28

Similar Documents

Publication Publication Date Title
MY202221A (en) Heterocyclic compound and use thereof
EA201891742A1 (en) SUBSTITUTED PIPERIDINE CONNECTION AND ITS APPLICATION
EA202192138A1 (en) HETEROCYCLIC COMPOUND AND ITS APPLICATIONS
CY1122821T1 (en) 1,3-BENZODIOXOLE DERIVATIVES AS EZE1 AND/OR EZE2 INHIBITORS
EA201892128A1 (en) HETEROCYCLIC AMIDES USEFUL AS MODULATORS
MD3269370T2 (en) Novel condensed pyrimidine compound or salt thereof
EA201890749A1 (en) ACETHYL-COA-CARBOXYLASE INHIBITORS (ACC) AND THEIR APPLICATION
MX2018010192A (en) Glycosidase inhibitors.
EA201891910A1 (en) PAD4 HETEROARYLINARY INHIBITORS
MX2017002670A (en) Glycosidase inhibitors.
EA201990044A1 (en) HETEROCYCLIC COMPOUNDS AS ANTIBACTERIAL MEANS
EA201891409A1 (en) BENZAMIDE COMPOUNDS AND THEIR APPLICATION AS HERBICIDES
EA201491936A1 (en) NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
BR112017026682A2 (en) new bicyclic compounds as dual action inhibitors of atx / ca
EA201992306A1 (en) IP6K INHIBITORS
EA201691982A1 (en) 5,6-Disposable Pyridine-2-Carboxamides as Agonists of Cannabinoid Receptors
PH12020550403A1 (en) Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
EA201890889A1 (en) COMPOSITION CONTAINING NIACINAMIDE AND PICOLINAMIDE
EA201690523A1 (en) TRIAZOLOPIRIDIN, COMPOSITIONS AND METHODS OF THEIR APPLICATION
EA201790464A1 (en) HETEROBICYCLIC COMPOUNDS AND THEIR APPLICATION FOR THE TREATMENT OF TUBERCULOSIS
MX2015016332A (en) Pyrrolotriazines as alk inhibitors.
EA201990952A1 (en) Pyridonic Compound as a c-Met Inhibitor
EA201892449A1 (en) Condensed Heterocyclic Compounds
EA202090428A1 (en) HETEROCYCLIC COMPOUND AND ITS APPLICATION
PH12020500432A1 (en) Compounds and methods for treating hyperkalemia